收藏切换
Analysis of the clinical prescription of semaglutide
收藏切换
PDF
Bin ZHANG, Ke-lu HOU, Yue CHEN, Hai-ying ZHANG
Chinese Journal of Clinical Pharmacology | 2025, 41(6) : 881 - 885
Less
收藏切换
Chinese Journal of Clinical Pharmacology | 2025, 41(6): 881-885
Reader’s Field
Analysis of the clinical prescription of semaglutide
Full
Bin ZHANG, Ke-lu HOU, Yue CHEN, Hai-ying ZHANG
Affiliations
  • Department of Pharmacy, Peking University People′s Hospital, Beijing 100044, China
Published: 2025-03-28 doi: 10.13699/j.cnki.1001-6821.2025.06.025
Outline
收藏切换
Objective

To investigate prescription of semaglutide and analyzed status of semaglutide administration in China’s real-world.

Methods

The prescription including semaglutide were extracted from 9 cities across China in first quarter of 2023. We analyzed the current administration of semaglutide and risk factors of off-label use of semaglutide by multivariant logistic regression.

Results

A total of 10 884 patients were included after data screening, about 70% patients were 34-64 years old. Endocrinology was the most common prescription department. Diabetes was diagnosed in 76.78% patients and 765 patients combined chronic complications of diabetes, of which diabetic neuropathy (470 cases, 4.32%) and diabetic nephropathy (248 cases, 2.28%) were the most common complications. Cardiovascular diseases and risk factors were diagnosed in 2 429 patients. Hypertension (1 379 cases, 12.67%) and hyperlipemia (1 342 cases, 11.31%) were the most common cardiovascular disease and risk factors. While 56.74% (6 176 cases) patients were treated by semaglutide singe-agent in general, 36.79% (3 075 cases/ 8 357 cases) patients with diabetes combined oral hypoglycemic drugs or insulin, and biguanides and sodium-dependent glucose transporters 2 inhibitors were used mostly. About 1/4 patients without diabetes off-label administrated semaglutide. According to the logistic regression, risk factors of off-label use were elder age, came from first-tier cities, prescription from endocrinology and a greater number of combined cardiovascular diseases and risk factors.

Conclusion

Semaglutide -based therapy regimens in patients with diabetes are fairly standardized according to clinical guidelines, while off-label use in patients without diabetes are supported by clinical evidence and guidelines to some extent.

semaglutide  /  real-world  /  off-label administration
Bin ZHANG, Ke-lu HOU, Yue CHEN, Hai-ying ZHANG. Analysis of the clinical prescription of semaglutide[J]. Chinese Journal of Clinical Pharmacology, 2025 , 41 (6) : 881 -885 . DOI: 10.13699/j.cnki.1001-6821.2025.06.025
Year 2025 volume 41 Issue 6
PDF
0
0
Cite this Article
BibTeX
Article Info
doi: 10.13699/j.cnki.1001-6821.2025.06.025
  • Receive Date:2024-10-11
  • Online Date:2026-08-04
  • Published:2025-03-28
Article Data
Affiliations
History
  • Received:2024-10-11
Funding
Affiliations
    Department of Pharmacy, Peking University People′s Hospital, Beijing 100044, China
References
Share
https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/10.13699/j.cnki.1001-6821.2025.06.025
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT